Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • Bone Marrow & Stem Cell Transplant
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Targeted Therapy
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • Bone Marrow & Stem Cell Transplant
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Targeted Therapy
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Eisai and BMS end global strategic collaboration for the co-development and co-commercialization of farletuzumab ecteribulin; now all rights with Eisai 

July 9, 2024

Radionetics Oncology Enters Into Strategic Agreement With Lilly

July 9, 2024

TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta’s KVA12123 Novel anti-VISTA Checkpoint Inhibitor

July 9, 2024

IASO Bio and Innovent Enhance Strategic Collaboration in Cell Therapy

July 9, 2024

Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced NET based on positive CABINET Ph 3 trial

July 9, 2024

Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat for the Treatment of Metastatic CRPC

July 9, 2024

Ubix Therapeutics and Yuhan Announce Exclusive License Agreement for UBX-103 for Treatment of Metastatic CRPC

July 9, 2024

Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371 

July 9, 2024

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies

July 1, 2024

Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation

June 25, 2024

Day One Expands Pipeline with Potential First-in-Class Clinical-Stage ADC Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

June 25, 2024

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

June 25, 2024

Lead Selection for MDG2021 Announced, Expanding TCR-T KRAS Library Targeting Solid Tumors

June 25, 2024

Xencor Regains CD20 x CD3 Bispecific T-Cell Engager

June 18, 2024

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib

June 18, 2024

Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors

June 18, 2024

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

June 18, 2024

Immutep and MSD to Evaluate Efti in Combination with KEYTRUDA in Pivotal Ph 3 TACTI-004 Trial

June 11, 2024

FibroGen Announces Clinical Trial Supply Agreement with Regeneron to Evaluate FG-3165 and FG-3175 in Combination with LIBTAYO in Upcoming Clinical Trials

June 11, 2024

Champions Oncology and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development

June 11, 2024

Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform 

June 11, 2024

QUANTRO Therapeutics Reaches A Milestone In The Collaboration With Boehringer Ingelheim To Develop First-In-Class Cancer Treatments

June 11, 2024

I-Mab Announces Collaboration with BMS to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

June 11, 2024

Notice of Allowance issued for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

June 11, 2024

Alphamab Oncology Collaborated with ArriVent in relation to the Research, Development and Commercialization of ADC Products

June 11, 2024
Page1 … Page23 Page24 Page25 Page26 Page27 … Page41

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.